Develops immunotherapies for autoimmune type 1 diabetes.
Dec 2025Revenue $0.00/yrExpenses $49.0M/yr
Fell below break-even Aug 2021Cash runway ≈ 1.9 years from Jun 2026
Figures by year
When will SAB Biotherapeutics be profitable again?
Its expenses passed its revenue in Aug 2021. In the 12 months to Dec 2025, revenue was $0.00 and expenses $49.0M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $49.0M | −$49.0M |
| Dec 2024 | $1.32M | $44.2M | −$42.9M |
| Dec 2023 | $2.24M | $40.3M | −$38.1M |
| Dec 2022 | $23.9M | $52.8M | −$28.9M |
| Dec 2021 | $60.9M | $74.3M | −$13.4M |
| Dec 2020 | $55.2M | $34.7M | $20.6M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.